BRCA-targeting drug olaparib could offer hope for women with advanced breast cancer with inherited mutation 27 Feb 2017 AstraZeneca has issued a statement saying a phase III trial of the ovarian cancer drug olaparib significantly delayed progression of advanced breast cancer in women with BRCA mutations. But what does this news mean for patients? Find out more Show/Hide